Cochrane · systematic review · CD006826
Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Nannini, LJ, Poole, P, Milan, SJ, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 1 · 14.3%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
All combined inhalers－participants with one or more exacerbations
Population: patients with COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation rates per participant per year | Rate ratio 0.87 [0.8, 0.94] | 6 studies · 5601 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
Mortality | OR 0.78 [0.64, 0.94] | 12 studies · 7518 participants | High |
Pneumonia | OR 1.08 [0.91, 1.28] | 12 studies · 7320 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Hospitalisations due to COPD exacerbations | OR 0.93 [0.8, 1.07] | 10 studies · 7060 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events－serious Fluticasone/salmeterol (FPS) versus fluticasone (FP) | OR 1.05 [0.82, 1.34] | 7 studies · 5055 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events－serious events Budesonide/formoterol (BDF) versus budesonide (BD) | OR 0.93 [0.72, 1.21] | 3 studies · 1469 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events－serious Mometasone/formoterol (MF/F) versus Mometasone (MF) | OR 1.03 [0.63, 1.67] | 2 studies · 905 participants | Low Downgraded: risk of bias, imprecision, inconsistency |